Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Metrics to compare | RPTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRPTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −5.3x | −0.5x | |
PEG Ratio | −0.06 | −0.19 | 0.00 | |
Price/Book | 0.3x | 1.3x | 2.6x | |
Price / LTM Sales | 1.0x | 11.2x | 2.9x | |
Upside (Analyst Target) | - | 321.1% | 66.3% | |
Fair Value Upside | Unlock | 3.6% | 10.2% | Unlock |